Floatz logo

mln9708

Higher-risk Myelodysplastic Syndrome

CellCentric Ltd.Phase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Higher-risk Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Inobrodib
CellCentric Ltd.
Phase 1/2CCC
Mezigdomide
CellCentric Ltd.
Phase 1/2CCC
Elranatamab
CellCentric Ltd.
Phase 1/2CCC
Teclistamab
CellCentric Ltd.
Phase 1/2CCC
3d189
3D Medicines
Phase 1CC

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Hematopoietic Cell Transplantation RecipientDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →